Neutralizing CCL1 or inhibiting CCL1 signaling reduces pulmonary fibrosis in vitro and in vivo, indicating that CCL1 is a potential therapeutic target for IPF (8). This evidence concerns the gene CCL1 and idiopathic pulmonary fibrosis.